| Literature DB >> 15837308 |
Clinton M Yeung1, Larry L Klein, Charles A Flentge, John T Randolph, Chen Zhao, MingHua Sun, Tatyana Dekhtyar, Vincent S Stoll, Dale J Kempf.
Abstract
The need for a potent HIV protease inhibitor (PI) to combat emerging PI-resistant viruses is anticipated. Analogs formulated from the combination of structural fragments of Ritonavir, Lopinavir, and Amprenavir were synthesized. Analogs containing the oxime pharmacophore were found to have improved activities against both wild type and resistant (A17) viruses. The synthesis and structure-activity relationships (SAR) based upon the in vitro IC50 of this series of compounds are reported.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15837308 DOI： 10.1016/j.bmcl.2005.03.008
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823